Editorial: Advances in targeted therapy and biomarker research for endocrine-related cancers.
作者信息
Wu Yang, Zhang Zili
机构信息
School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Pancreas Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
出版信息
Front Endocrinol (Lausanne). 2024 Dec 11;15:1533623. doi: 10.3389/fendo.2024.1533623. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Advances in targeted therapy and biomarker research for endocrine-related cancers.社论：内分泌相关癌症的靶向治疗与生物标志物研究进展
Front Endocrinol (Lausanne). 2024 Dec 11;15:1533623. doi: 10.3389/fendo.2024.1533623. eCollection 2024.
2
Criteria for assessing evidence for biomarker-targeted therapies in rare cancers-an extrapolation framework.评估罕见癌症中生物标志物靶向治疗证据的标准——一种外推框架。
Ther Adv Med Oncol. 2024 Sep 2;16:17588359241273062. doi: 10.1177/17588359241273062. eCollection 2024.
3
Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer.甲状腺癌中生物标志物驱动的靶向治疗进展
Cancers (Basel). 2021 Dec 9;13(24):6194. doi: 10.3390/cancers13246194.
4
Next-generation sequencing for endocrine cancers: Recent advances and challenges.内分泌癌的下一代测序：最新进展与挑战
Tumour Biol. 2017 May;39(5):1010428317698376. doi: 10.1177/1010428317698376.
5
Advances in targeted therapy and biomarker research in thyroid cancer.甲状腺癌的靶向治疗和生物标志物研究进展。
Front Endocrinol (Lausanne). 2024 Mar 4;15:1372553. doi: 10.3389/fendo.2024.1372553. eCollection 2024.
6
Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade.靶向放射性核素治疗在内分泌相关癌症中的应用：近十年的进展。
Front Endocrinol (Lausanne). 2023 Nov 20;14:1187870. doi: 10.3389/fendo.2023.1187870. eCollection 2023.
7
Extrapolating evidence for molecularly targeted therapies from common to rare cancers: a scoping review of methodological guidance.从常见癌症外推到罕见癌症的分子靶向治疗证据：方法学指导的范围综述。
BMJ Open. 2022 Jul 12;12(7):e058350. doi: 10.1136/bmjopen-2021-058350.
8
Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.乳腺密度、内分泌治疗与乳腺癌风险：预后和预测生物标志物综述。
Cochrane Database Syst Rev. 2021 Oct 26;10(10):CD013091. doi: 10.1002/14651858.CD013091.pub2.
9
Editorial: Gynecological and gastrointestinal cancers: Recent advances in molecular diagnosis and targeted therapy.社论：妇科与胃肠道癌症：分子诊断与靶向治疗的最新进展
Front Mol Biosci. 2023 Mar 3;10:1167337. doi: 10.3389/fmolb.2023.1167337. eCollection 2023.
10
Editorial: Pharmacometabolomics: biomarker discovery, precision medicine, technical advances, perspectives and future applications in respiratory diseases.社论：药物代谢组学：生物标志物发现、精准医学、技术进展、呼吸系统疾病的前景及未来应用
Front Mol Biosci. 2023 Aug 30;10:1268001. doi: 10.3389/fmolb.2023.1268001. eCollection 2023.
引用本文的文献
1
The construction and evaluation of a prognostic risk score model for HCC based on MPT-related lncRNAs.基于MPT相关长链非编码RNA的肝癌预后风险评分模型的构建与评估
Front Oncol. 2025 Jul 28;15:1590094. doi: 10.3389/fonc.2025.1590094. eCollection 2025.
2
Gastrointestinal Cancers with Consideration of DPD and UGT1A1 Plasma Levels: Chemotherapy-Related Toxicity.考虑DPD和UGT1A1血浆水平的胃肠道癌症：化疗相关毒性
Life (Basel). 2025 Jul 4;15(7):1071. doi: 10.3390/life15071071.
3
Identification of thyroid cancer biomarkers using WGCNA and machine learning.使用加权基因共表达网络分析（WGCNA）和机器学习鉴定甲状腺癌生物标志物
Eur J Med Res. 2025 Apr 5;30(1):244. doi: 10.1186/s40001-025-02466-x.
本文引用的文献
1
Local Exosome Inhibition Potentiates Mild Photothermal Immunotherapy Against Breast Cancer.局部外泌体抑制增强对乳腺癌的温和光热免疫疗法
Adv Sci (Weinh). 2025 Jan;12(2):e2406328. doi: 10.1002/advs.202406328. Epub 2024 Nov 22.
2
Hybrid Cell Membrane-Coated Nanoparticles for Synergizing Sonodynamic Therapy and Immunotherapy against Triple-Negative Breast Cancer.用于协同声动力疗法和免疫疗法治疗三阴性乳腺癌的混合细胞膜包覆纳米颗粒
Adv Healthc Mater. 2025 Jan;14(3):e2404184. doi: 10.1002/adhm.202404184. Epub 2024 Nov 21.
3
Spatial and Single-Cell Transcriptomics Unraveled Spatial Evolution of Papillary Thyroid Cancer.空间和单细胞转录组学揭示了甲状腺乳头状癌的空间演变
Adv Sci (Weinh). 2025 Jan;12(2):e2404491. doi: 10.1002/advs.202404491. Epub 2024 Nov 14.
4
Concerns Regarding Thermal Ablation for Papillary Thyroid Cancer.关于甲状腺乳头状癌热消融的担忧
JAMA Surg. 2024 Nov 1;159(11):1231-1232. doi: 10.1001/jamasurg.2024.2744.
5
Development of Melanoma and Other Nonkeratinocyte Skin Cancers After Thyroid Cancer Radiation.甲状腺癌放疗后黑色素瘤及其他非角质形成细胞皮肤癌的发生
JAMA Netw Open. 2024 Sep 3;7(9):e2434841. doi: 10.1001/jamanetworkopen.2024.34841.
6
Head and neck paragangliomas: Recent advances in translational and clinical research and guidelines for patient care.头颈部副神经节瘤：转化与临床研究的最新进展及患者护理指南
Best Pract Res Clin Endocrinol Metab. 2024 Dec;38(6):101951. doi: 10.1016/j.beem.2024.101951. Epub 2024 Sep 11.
7
Intratumoral Microbiome in Head and Neck Paragangliomas.头颈部副神经节瘤的瘤内微生物组。
Int J Mol Sci. 2024 Aug 23;25(17):9180. doi: 10.3390/ijms25179180.
8
Scinderin is a potential prognostic biomarker and correlated with immunological regulation: from pan-cancer analysis to liver hepatocellular carcinoma.Scinderin 是一种潜在的预后生物标志物，与免疫调节相关：从泛癌分析到肝肝细胞癌。
Front Immunol. 2024 Jul 23;15:1361657. doi: 10.3389/fimmu.2024.1361657. eCollection 2024.
9
A congress on head and neck paragangliomas: advancing clinical care.一场关于头颈部副神经节瘤的大会：推动临床护理发展。
Nat Rev Endocrinol. 2024 Jul;20(7):383-384. doi: 10.1038/s41574-024-00987-9.
10
A refined therapeutic plan based on the machine-learning prognostic model of liver hepatocellular carcinoma.基于机器学习的肝癌预后模型制定的精细化治疗方案。
Comput Biol Med. 2024 Feb;169:107907. doi: 10.1016/j.compbiomed.2023.107907. Epub 2023 Dec 26.
Zotero 插件